Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12679966 | 0.88 | CYP3A4 (0.49) | CYP3A4MLYCDCNR2TSHRALDH1A1 | |
| SCHEMBL1115070 | 0.85 | CYP3A4 (0.47) | CYP3A4MLYCDCNR2TSHRALDH1A1 | |
| SCHEMBL1114917 | 0.81 | CHRNB2 (0.47) | CYP3A4MLYCDTSHRALDH1A1GABBR2 | |
| SCHEMBL1115041 | 0.81 | CYP3A4 (0.48) | CYP3A4CNR2TSHRALDH1A1GLA | |
| SCHEMBL12679862 | 0.80 | CYP3A4 (0.45) | CYP3A4MLYCDCNR2TSHRALDH1A1 | |
| SCHEMBL3646180 | 0.77 | CYP3A4 (0.65) | CYP3A4CNR2TSHRALDH1A1GLA | |
| SCHEMBL1114850 | 0.74 | CYP3A4 (0.54) | CYP3A4CNR2TSHRALDH1A1GLA | |
| SCHEMBL11738442 | 0.73 | CYP3A4 (0.60) | CYP3A4CNR2TSHRALDH1A1GLA | |
| SCHEMBL1114715 | 0.73 | CYP3A4 (0.53) | CYP3A4MLYCDCNR2TSHRALDH1A1 | |
| SCHEMBL12679965 | 0.72 | CYP3A4 (0.46) | CYP3A4MLYCDCNR2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756039-B1 | Compounds and compositions for delivering active agents | EMISPHERE TECH INC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-1756039-B1 | Compounds and compositions for delivering active agents | EMISPHERE TECH INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8273794-B2 | 7-[isopropyl(phenyl)amino]-7-oxoheptanoic acid, 3-(2-Hydroxy-benzoylamino)-butyric acid, 4-Oxo-4-phenyl-butyric acid, 10-(2-Hydroxy-phenyl)-10-oxo-decanoic acid, 4-(4-Methoxy-phenyl)-4-oxo-butyric acid: promoting the absorption of the active agent | EMISPHERE TECHNOLOGIES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273794-B2 | 7-[isopropyl(phenyl)amino]-7-oxoheptanoic acid, 3-(2-Hydroxy-benzoylamino)-butyric acid, 4-Oxo-4-phenyl-butyric acid, 10-(2-Hydroxy-phenyl)-10-oxo-decanoic acid, 4-(4-Methoxy-phenyl)-4-oxo-butyric acid: promoting the absorption of the active agent | EMISPHERE TECHNOLOGIES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2279732-A2 | Compounds and compositions for delivering active agents | Emisphere Technologies, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-2279732-A2 | Compounds and compositions for delivering active agents | Emisphere Technologies, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20080255250-A1 | Compounds and Compositions for Delivering Active Agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255250-A1 | Compounds and Compositions for Delivering Active Agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255250-A1 | Compounds and Compositions for Delivering Active Agents | SERPINB1, ELANE, MMP8 | CYP3A4 3303/4885MLYCD 1941/4885CNR2 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.